Biosimilars: Company Strategies to Capture Value from the Biologics Market

Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to...

Full description

Bibliographic Details
Main Authors:	Juan Leonardo Martínez-Hurtado, Bruno Calo-Fernández
Format:	Article
Language:	English
Published:	MDPI AG 2012-12-01
Series:	Pharmaceuticals
Subjects:	biosimilar patent cliff biopharmaceutical industry market strategy biologics
Online Access:	http://www.mdpi.com/1424-8247/5/12/1393

id	doaj-ac13f8e0f6b94197b84f34669bfa4db8
record_format	Article
spelling	doaj-ac13f8e0f6b94197b84f34669bfa4db82020-11-25T03:23:39ZengMDPI AGPharmaceuticals1424-82472012-12-015121393140810.3390/ph5121393Biosimilars: Company Strategies to Capture Value from the Biologics MarketJuan Leonardo Martínez-HurtadoBruno Calo-FernándezPatents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.http://www.mdpi.com/1424-8247/5/12/1393biosimilarpatent cliffbiopharmaceutical industrymarket strategybiologics
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Juan Leonardo Martínez-Hurtado Bruno Calo-Fernández
spellingShingle	Juan Leonardo Martínez-Hurtado Bruno Calo-Fernández Biosimilars: Company Strategies to Capture Value from the Biologics Market Pharmaceuticals biosimilar patent cliff biopharmaceutical industry market strategy biologics
author_facet	Juan Leonardo Martínez-Hurtado Bruno Calo-Fernández
author_sort	Juan Leonardo Martínez-Hurtado
title	Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_short	Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_full	Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_fullStr	Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_full_unstemmed	Biosimilars: Company Strategies to Capture Value from the Biologics Market
title_sort	biosimilars: company strategies to capture value from the biologics market
publisher	MDPI AG
series	Pharmaceuticals
issn	1424-8247
publishDate	2012-12-01
description	Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximising the value generated from the biologics patent cliff.
topic	biosimilar patent cliff biopharmaceutical industry market strategy biologics
url	http://www.mdpi.com/1424-8247/5/12/1393
work_keys_str_mv	AT juanleonardomartinezhurtado biosimilarscompanystrategiestocapturevaluefromthebiologicsmarket AT brunocalofernandez biosimilarscompanystrategiestocapturevaluefromthebiologicsmarket
_version_	1724605171635322880

Biosimilars: Company Strategies to Capture Value from the Biologics Market

Similar Items